全球标靶治疗市场规模、份额、趋势和成长分析报告（2026-2034年）

预计标靶治疗市场将从 2025 年的 884.2 亿美元成长到 2034 年的 1,566.4 亿美元，2026 年至 2034 年的复合年增长率为 6.56%。

精准医疗和分子诊断技术的进步正推动全球标靶治疗市场快速成长。标靶治疗，尤其是在肿瘤领域，旨在特异性攻击疾病相关的分子通路，同时最大限度地减少对健康组织的损伤。癌症发病率的上升以及基于生物标记的治疗方法的日益普及是全球市场成长的主要驱动因素。

关键成长要素包括增加对基因组学研究的投资以及伴随诊断技术的开发。製药公司正加大对单株抗体、激酶抑制剂和基因疗法的研发投入。新型标靶治疗的监管核准以及对个人化治疗方法日益增长的需求，进一步推动了已开发市场和新兴市场的市场扩张。

展望未来，在免疫肿瘤学和联合治疗持续创新的推动下，市场预计将稳定成长。临床试验计画的拓展和健保报销机制的完善将提升病患获得治疗的机会。人工智慧在药物研发过程中的应用可望缩短研发週期。随着精准医疗的普及，标靶治疗有望主导未来的治疗策略。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章 全球标靶治疗市场：按类型划分

• 市场分析、洞察与预测
• 单株抗体
• 低分子化合物

第五章 全球标靶治疗市场：依应用划分

• 市场分析、洞察与预测
• 乳癌
• 结肠癌
• 白血病
• 肺癌
• 淋巴瘤
• 多发性硬化症
• 肾癌
• 老龄化黄斑部病变（湿性）
• 其他的

第六章 全球标靶治疗市场：依通路划分

• 市场分析、洞察与预测
• 医院药房
• 零售药房
• 网路药房

第七章 全球标靶治疗市场：按地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第八章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第九章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Sanofi
  • GlaxoSmithKline Plc
  • Takeda Pharmaceutical Company Ltd
  • Merck & Co. Inc
  • Novartis AG
  • Pfizer Inc
  • F. Hoffmann-La Roche Ltd
  • AstraZeneca
  • Seagen Inc
  • Bayer AG
  • Amgen Inc
  • Bristol-Myers Squibb

The Targeted Therapeutics Market size is expected to reach USD 156.64 Billion in 2034 from USD 88.42 Billion (2025) growing at a CAGR of 6.56% during 2026-2034.

The Global Targeted Therapeutics Market is experiencing rapid expansion due to advancements in precision medicine and molecular diagnostics. Targeted therapies are designed to specifically attack disease-related molecular pathways, particularly in oncology, minimizing damage to healthy tissues. Rising cancer prevalence and increasing adoption of biomarker-based treatment approaches are significantly driving market growth worldwide.

Key growth drivers include growing investments in genomics research and the development of companion diagnostics. Pharmaceutical companies are increasingly focusing on monoclonal antibodies, kinase inhibitors, and gene-based therapies. Regulatory approvals for novel targeted drugs and rising demand for personalized treatment regimens are further strengthening market expansion across developed and emerging regions.

Looking ahead, the market is expected to witness robust growth supported by continuous innovation in immuno-oncology and combination therapies. Expanding clinical trial pipelines and improved reimbursement frameworks will enhance accessibility. Integration of artificial intelligence in drug discovery processes may accelerate development timelines. As precision medicine becomes mainstream, targeted therapeutics will likely dominate future treatment strategies.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type

• Monoclonal Antibodies
• Small Molecule

By Application

• Breast Cancer
• Colorectal Cancer
• Leukemia
• Lung Cancer
• Lymphoma
• Multiple Sclerosis
• Renal Cancer
• Wet Age-related Macular Degeneration
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

COMPANIES PROFILED

• Sanofi, GlaxoSmithKline plc, Takeda Pharmaceutical Company Ltd, Merck Co Inc, Novartis AG, Pfizer Inc, F HoffmannLa Roche Ltd, AstraZeneca, Seagen Inc, Bayer AG, Amgen Inc, BristolMyers Squibb
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL TARGETED THERAPEUTICS MARKET: BY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. Monoclonal Antibodies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Small Molecule Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL TARGETED THERAPEUTICS MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Breast Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Colorectal Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Leukemia Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Lung Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Lymphoma Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Multiple Sclerosis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.8. Renal Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.9. Wet Age-related Macular Degeneration Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.10. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL TARGETED THERAPEUTICS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel
• 6.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL TARGETED THERAPEUTICS MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Type
  • 7.2.2 By Application
  • 7.2.3 By Distribution Channel
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Type
  • 7.3.2 By Application
  • 7.3.3 By Distribution Channel
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Type
  • 7.4.2 By Application
  • 7.4.3 By Distribution Channel
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Type
  • 7.5.2 By Application
  • 7.5.3 By Distribution Channel
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Type
  • 7.6.2 By Application
  • 7.6.3 By Distribution Channel
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL TARGETED THERAPEUTICS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Sanofi
  • 9.2.2 GlaxoSmithKline Plc
  • 9.2.3 Takeda Pharmaceutical Company Ltd
  • 9.2.4 Merck & Co. Inc
  • 9.2.5 Novartis AG
  • 9.2.6 Pfizer Inc
  • 9.2.7 F. Hoffmann-La Roche Ltd
  • 9.2.8 AstraZeneca
  • 9.2.9 Seagen Inc
  • 9.2.10 Bayer AG
  • 9.2.11 Amgen Inc
  • 9.2.12 Bristol-Myers Squibb